CAMBRIDGE, Mass. & BRUSSELS--(BUSINESS WIRE)--Technology company MC10 Inc. and global biopharmaceutical company UCB announced that they have entered into a partnership to develop MC10’s Biostamp™ platform for patient-focused disease management solutions. The collaboration will evaluate the integration of MC10’s novel, conformal sensing platform with UCB’s pharmaceutical products to make a positive difference in the lives of people living with severe neurological disorders.
Help employers find you! Check out all the jobs and post your resume.